Goldman Sachs Group Inc Avalo Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$3.0 - $10.45 $1.95 Million - $6.79 Million	649,653 New	649,653 $324,000
Q2 2022 Aug 15, 2022	BUY	$3.0 - $10.45 $374,307 - $1.3 Million	124,769 Added 23.77%	649,653 $324,000
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $1.21 Million - $3.48 Million	-160,380 Reduced 23.4%	524,884 $380,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $247,968 - $361,368	12,600 Added 1.87%	685,264 $1.17 Million
Q3 2021 Nov 10, 2021	BUY	$26.16 - $40.68 $17.6 Million - $27.4 Million	672,664 New	672,664 $1.47 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $92.7M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.